The baseline paper of the AMYPAD Diagnostic Study has been published

17/06/2022

The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) consortium recently published a paper which presents the participants’ baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS). This study aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. A total of 840 participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics. The aim of this article is to discuss the implemented enrollment strategies and describe the baseline features of the AMYPAD DPMS participants in order to assess whether the sample is representative of a wider memory clinic population and to ensure that the future study results will be reliable and generalisable. The paper entitled “Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study” has been published in the journal Alzheimer’s & Dementia, the journal of the Alzheimer’s Association and can be read here: https://doi.org/10.1002/alz.12696